Get the Stockscreener App
8.70
4.29%
-0.39
Arcus Biosciences Inc stock is traded at $8.70, with a volume of 861.57K.
It is down -4.29% in the last 24 hours and up +1.64% over the past month.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
See More
Previous Close:
$9.09
Open:
$9
24h Volume:
861.57K
Relative Volume:
0.74
Market Cap:
$1.06B
Revenue:
$247.00M
Net Income/Loss:
$-249.00M
P/E Ratio:
-2.8155
EPS:
-3.09
Net Cash Flow:
$-267.00M
1W Performance:
-13.17%
1M Performance:
+1.64%
6M Performance:
-45.90%
1Y Performance:
-46.30%
1-Day Range:
$8.69
$9.18
1-Week Range:
$8.69
$10.15
52-Week Range:
$6.50
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
8.70 | 1.06B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
(RCUS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
GAMMA Investing LLC Buys 15,466 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences’ SWOT analysis: promising cancer therapy stock faces pivotal year - Investing.com
Arcus Biosciences Sees Unusually High Options Volume (NYSE:RCUS) - Defense World
Arcus Biosciences Holds Annual Stockholders Meeting - TipRanks
Arcus Biosciences Inc Inc. (RCUS) Price Performance: A Technical Analysis Perspective - investchronicle.com
Positive Signs As Multiple Insiders Buy Arcus Biosciences Stock - simplywall.st
Arcus Biosciences Announces New Employment Inducement Grants | R - GuruFocus
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 7,872 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Cantor Fitzgerald Comments on RCUS FY2026 Earnings - Defense World
Arcus Biosciences Announces New Employment Inducement Grants | RCUS Stock News - GuruFocus
Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
When the Price of (RCUS) Talks, People Listen - news.stocktradersdaily.com
Nuveen Asset Management LLC Has $1.96 Million Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Bank of America Corp DE - Defense World
Arcus Biosciences (RCUS) Unveils Promising Data for Cancer Treat - GuruFocus
Transcript : Arcus Biosciences, Inc.Special Call - marketscreener.com
Arcus Biosciences Presents Promising Phase 1/1b Trial Data - TipRanks
Two Sigma Investments LP Purchases 11,027 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences (RCUS) Unveils Promising Data for Cancer Treatment | RCUS Stock News - GuruFocus
Arcus Says Initial Data From The Arc-20 Study Of Casdatifan Plus Cabozantinib Showed Nearly Half Of Patients With Metastatic Kidney Cancer Had A Confirmed Response - marketscreener.com
ProShare Advisors LLC Increases Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences (NYSE:RCUS) Shares Down 8.6% – Here’s What Happened - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Arcus Biosciences’ SWOT analysis: stock’s potential in cancer therapy market By Investing.com - Investing.com Nigeria
BNP Paribas Financial Markets Purchases 9,016 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Deutsche Bank AG Boosts Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences’ SWOT analysis: stock’s potential in cancer therapy market - Investing.com
Lazard Asset Management LLC Has $93,000 Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Barclays Reaffirms Their Buy Rating on Arcus Biosciences (RCUS) - The Globe and Mail
Discovery of AB801, a Potent and Selective Inhibitor of AXL Receptor Tyrosine Kinase for Use in Cancer Therapy - ACS Publications
Recent Investment Analysts’ Ratings Changes for Arcus Biosciences (RCUS) - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Northern Trust Corp - Defense World
Arcus Biosciences Stock May Be The Next To Fail (NYSE:RCUS) - Seeking Alpha
Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Just Slashed This Year's Revenue Estimates By 17% - simplywall.st
Trading (RCUS) With Integrated Risk Controls - news.stocktradersdaily.com
Price T Rowe Associates Inc. MD Sells 6,265 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Morgan Stanley Cuts Arcus Biosciences (NYSE:RCUS) Price Target to $22.00 - Defense World
First Trust Advisors LP Has $264,000 Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Cantor Fitzgerald Has Weak Forecast for RCUS FY2025 Earnings - Defense World
HC Wainwright Predicts Weaker Earnings for Arcus Biosciences - Defense World
Arcus Biosciences (RCUS): Morgan Stanley Lowers Price Target | R - GuruFocus
Wedbush Decreases Earnings Estimates for Arcus Biosciences - Defense World
Raymond James Financial Inc. Makes New Investment in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Morgan Stanley Lowers Price Target on Arcus Biosciences to $22 From $24, Keeps Overweight Rating - marketscreener.com
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates - MSN
Goldman Sachs Adjusts Price Target for Arcus Biosciences (RCUS) - GuruFocus
Goldman Sachs Adjusts Price Target for Arcus Biosciences (RCUS) | RCUS Stock News - GuruFocus
Wells Fargo Adjusts Price Target for Arcus Biosciences (RCUS) to $26 | RCUS Stock News - GuruFocus
Arcus Biosciences First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Arcus Biosciences (RCUS) Receives Adjusted Price Target from Wel - GuruFocus
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):